# TAU N279K Research Report **Protein:** TAU N279K **Variant:** N279K **UniProt ID:** P10636 **Disease Association:** Alzheimer's disease **Report Generated:** 2026-07-29 21:39 UTC **AlphaFold Confidence (pLDDT):** 54.3% **Structure Folded:** 2026-07-21 --- ## Structure Summary The N279K variant in tau protein, which is linked to Alzheimer's disease, was analyzed using computational structure prediction to understand how this genetic change might affect the protein. The analysis achieved a moderate confidence score (pLDDT of 54.3), indicating significant uncertainty about the predicted structure, which reflects tau's naturally disordered character. This low confidence level means the structural predictions should be interpreted cautiously and cannot definitively show how N279K alters tau's behavior, though the variant occurs in a functionally important region where tau interacts with other molecules. --- Tau protein is essential for stabilizing microtubules (the cell's internal scaffolding) in brain neurons, but in Alzheimer's disease, tau becomes abnormally modified and aggregates into toxic tangles that correlate strongly with cognitive decline [4][5]. The N279K variant, where asparagine at position 279 is replaced by lysine, introduces a dramatic change from a polar, uncharged amino acid to a positively charged one. This substitution occurs in tau's proline-rich region, a segment that normally mediates interactions with other proteins and contributes to tau's regulatory functions. The structural analysis of N279K tau was performed using AlphaFold2 computational modeling, which predicted three-dimensional structures based on evolutionary information and physical principles. However, the average confidence score (pLDDT of 54.3) falls well below the threshold of 70 typically considered reliable for structural interpretation. This low confidence reflects tau's intrinsic disorder—unlike many proteins that fold into stable, well-defined shapes, tau naturally exists as a flexible, shape-shifting molecule. Regions with pLDDT below 70 indicate the prediction algorithm cannot confidently determine a single structural arrangement, which is expected for intrinsically disordered proteins like tau. The N279K substitution introduces a positive charge in a region critical for tau's protein-protein interactions. In principle, this charge change could alter how tau binds to microtubules, how it interacts with kinases that modify tau, or how it aggregates into pathological tangles. Research has demonstrated that tau pathology involves both abnormal phosphorylation and propagation of misfolded tau between cells [1][4], and genetic variants can influence these processes. However, the low structural confidence for N279K means we cannot reliably visualize specific conformational changes or predict precise molecular consequences from the computational model alone. The clinical context of tau variants is complex. While most Alzheimer's disease cases involve accumulation of both amyloid-beta plaques and tau tangles [3][5], the density and distribution of tau tangles correlates more strongly with cognitive symptoms than amyloid burden. Studies have identified genetic factors that influence tau deposition patterns [2], and patient-derived models have shown that human neurons may have unique vulnerabilities to tau pathology not captured in animal models [4]. The introduction of a charged residue at position 279 could theoretically affect any of these processes, but experimental validation would be needed to determine the actual functional impact. Given the moderate confidence of these structural predictions, the findings should be considered preliminary hypotheses rather than definitive structural insights. The computational model suggests that N279K may alter tau's local electrostatic environment and potentially its interaction interfaces, but experimental techniques such as biochemical binding assays, phosphorylation studies, or aggregation kinetics would be necessary to confirm how this variant actually affects tau function and its role in Alzheimer's disease pathology. ## Works Cited [1] Zemke et al. (2026). The NORAD -pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42427771/) [2] Gunasekaran et al. (2026). Common and rare variant analyses implicate JARID2 in cerebral tau deposition. NPJ dementia. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42404994/) [3] Bittner et al. (2026). Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. EBioMedicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42468111/) [4] Ji et al. (2026). Patient-derived tau-seeded human neuronal chimeras recapitulate mature Alzheimer's tau pathology and uncover human-specific neuronal vulnerability. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42465485/) [5] Smirnov et al. (2026). Neurofibrillary tangle distribution in posterior cortical atrophy and typical early-onset Alzheimer's Disease. Free neuropathology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42453899/) ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | frontotemporal dementia | 0.789 | genetic_literature, clinical, literature, genetic_association, animal_model | | Pick disease | 0.757 | literature, animal_model, genetic_association, genetic_literature | | supranuclear palsy, progressive, 1 | 0.725 | literature, animal_model, genetic_association, genetic_literature | | Progressive supranuclear palsy - parkinsonism | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Atypical progressive supranuclear palsy | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Classical progressive supranuclear palsy | 0.696 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy-parkinsonism syndrome | 0.647 | animal_model, genetic_association, genetic_literature | | late-onset Parkinson disease | 0.639 | literature, animal_model, genetic_association, genetic_literature | | semantic dementia | 0.639 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy | 0.614 | genetic_literature, clinical, literature, genetic_association, animal_model | *...and 3339 more associations* --- ## Agent Findings ### Literature (1) - **2026-07-21:** None of these papers are directly relevant to the TAU N279K variant. While multiple papers discuss tau pathology, phosphorylation, MAPT gene regulation, and tau-related biomarkers in Alzheimer's disease, none specifically investigate the N279K amino acid substitution in the tau protein or its role in AD pathogenesis. The papers provide general context about tau biology but lack specific information about this particular variant. ### Clinical (1) - **2026-07-21:** ### Structural (1) - **2026-07-22:** AlphaFold structure update: Baseline check: 9 structure(s) found ### Synthesis (1) - **2026-07-22:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): Synthesis JSON could not be parsed; raw response is in agent logs.... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)